Paris, France -- Theraclion, a medical device company specializing in the development of non-invasive solutions for the treatment of thyroid nodules and parathyroid glands diseases, today announced the appointment of Ismael Nujurally MD as its new CEO.
“We are delighted by Ismael’s arrival at Theraclion”, commented Philippe Pouletty MD, Managing Director of Truffle Capital, who added that “his knowledge of the various healthcare systems and his awareness of medical device markets worldwide will boost our international ambitions”, he adds.
Ismael Nujurally is also very enthusiastic, commenting “I am really pleased to be joining Theraclion’s dynamic, ambitious team. There are some huge opportunities out there and we intend to seize them!”
Following his specialization in pathology and emergency medicine, then marketing, Ismael Nujurally has accumulated over 25 years of solid medical device industry experience. He has worked for Abbott France, Bard France, Graseby Medical/Smithgroup, American Medical Systems (Pfizer), Tyco Healthcare France, Oxford Instruments (Viasys), and, most recently, Credes Ltd.
Immediately prior to joining Theraclion, Ismael Nujurally had served as CEO at Credes Ltd since 2005. From 2002 to 2005, he worked as International Sales Director for Oxford Instruments Medical, helping the company post its first profits since 1997. He also gained industry visibility as General Manager of Tyco Healthcare France’s surgical division from 1999 to 2002, American Medical Systems’ Commercial Director for Europe, the Middle East & Africa, Graseby Medical’s International Marketing Manager and Bard France’s Product Manager & Commercial Director. Ismael Nujurally started his business career in 1988 as a Sales Representative at Abbott France and left the company 3 years later as a Product Manager.
About Theraclion
Incorporated in 2004, Theraclion is a hi-tech spin-out from EDAP-Technomed and the INSERM (the French National Institute for Healthcare and Medical Research). The company is developing an innovative therapeutic technology for reducing the volume of thyroid nodules and parathyroid glands. Theraclion’s HIFU (High-Intensity Focused Ultrasound)-based technology provides a non-invasive, outpatient alternative to surgery for certain pathologies.
Theraclion has already raised €3.5 million in funding from Truffle Capital, its longstanding lead investor.
Theraclion is targeting private and public hospitals in Europe, Asia and the USA. The company is notably taking the necessary steps towards FDA approval of its products, since the American market represents 50% of the global market.
For further information, visit www.theraclion.fr
